These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9864550)

  • 1. [Somatostatin agonists in the treatment of acromegaly].
    Jaquet P; Morange-Rahos I; Janano B; Moati P; Brue T
    Ann Endocrinol (Paris); 1998 Nov; 59(4):301-4. PubMed ID: 9864550
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of radiotherapy in acromegaly.
    González B; Vargas G; Espinosa-de-los-Monteros AL; Sosa E; Mercado M
    Arch Med Res; 2011 Jan; 42(1):48-52. PubMed ID: 21376263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin tensile properties in patients treated for acromegaly.
    Braham C; Betea D; Piérard-Franchimont C; Beckers A; Piérard GE
    Dermatology; 2002; 204(4):325-9. PubMed ID: 12077539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary gland: Medical therapy for acromegaly: can we predict response?
    Giustina A; Porcelli T
    Nat Rev Endocrinol; 2009 Aug; 5(8):425-7. PubMed ID: 19629067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus statement: medical management of acromegaly.
    Melmed S; Casanueva F; Cavagnini F; Chanson P; Frohman LA; Gaillard R; Ghigo E; Ho K; Jaquet P; Kleinberg D; Lamberts S; Laws E; Lombardi G; Sheppard MC; Thorner M; Vance ML; Wass JA; Giustina A
    Eur J Endocrinol; 2005 Dec; 153(6):737-40. PubMed ID: 16322377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society.
    ;
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3099-102. PubMed ID: 15240576
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert consensus document: A consensus on the medical treatment of acromegaly.
    Giustina A; Chanson P; Kleinberg D; Bronstein MD; Clemmons DR; Klibanski A; van der Lely AJ; Strasburger CJ; Lamberts SW; Ho KK; Casanueva FF; Melmed S;
    Nat Rev Endocrinol; 2014 Apr; 10(4):243-8. PubMed ID: 24566817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
    J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
    Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
    Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery.
    Wu TE; Lin HD; Lu RA; Wang ML; Chen RL; Chen HS
    Growth Horm IGF Res; 2010 Dec; 20(6):411-5. PubMed ID: 20943425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of somatostatin analogs on biochemical parameters in acromegaly.
    Liuzzi A; Marzullo P
    J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?
    Grasso LF; Pivonello R; Colao A
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):288-94. PubMed ID: 22627686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
    Selvarajah D; Webster J; Ross R; Newell-Price J
    Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
    Bandgar TR; Sarathi V; Shivane V; Bansode N; Menon PS; Shah NS
    J Postgrad Med; 2010; 56(1):7-11. PubMed ID: 20393242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical monitoring of disease activity after surgery for acromegaly.
    Shalet SM
    J Clin Endocrinol Metab; 2004 Feb; 89(2):492-4. PubMed ID: 14764750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.